Clinical trials: Ulcerative Colitis in Remission
Ulcerative Colitis
A Study of Tofacitinib in Patients With Ulcerative Colitis in Stable Remission
This study is a follow up study for subjects with Ulcerative Colitis (UC) in stable remission designed to evaluate flexible dosing of CP-690,550.
- Trial name
- NCT03281304
- Testing
- CP-690,500 5 mg, CP-690,550 10 mg
- Where
- 80 sites in United States, Belgium and 18 more
- Volunteers
- 140 people
- Sponsor
- Pfizer
Ulcerative Colitis
A Comparison of Once a Day Dose Compared to 2 Doses/Day
The purpose of this study is to compare the efficacy in maintaining remission of ulcerative colitis between a once daily (QD) Asacol regimen and a divided, twice daily (BID) Asacol dosing regimen.
- Trial name
- NCT00505778
- Testing
- Mesalamine Once-Daily, Mesalamine Twice-Daily
- Where
- 245 sites in United States, Canada and 1 more
- Volunteers
- 1,027 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis
Efficacy and Safety of SPD476 in Maintaining Remission in Patients With Ulcerative Colitis
Ulcerative colitis is a disease of the large bowel (colon) and rectum in which the lining of the bowel becomes red and swollen. Over time, patients with this disease may experience acute episodes of diarrhea, rectal bleeding and…
- Trial name
- NCT00151892
- Testing
- SPD476, Asacol
- Where
- 142 sites in United States, Argentina and 26 more
- Volunteers
- 829 people
- Sponsor
- Shire
Ulcerative Colitis
Long-Term Safety and Tolerability of Mesalamine Pellets in Participants With Ulcerative Colitis in Remission
To evaluate the long-term safety and tolerability of encapsulated mesalamine Granules (eMG) (formerly referred to as Mesalamine Pellets [MP]) in participants with ulcerative colitis currently in remission.
- Trial name
- NCT00326209
- Testing
- Encapsulated Mesalamine Granules (eMG)
- Where
- 61 sites in United States
- Volunteers
- 393 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
(CB-01-02/04) Extension Study of Budesonide Multi-Matrix System (MMX) 6 mg in Maintenance Of Remission In Patients With Ulcerative Colitis.
Randomized, double-blind, comparative study versus placebo performed in patients from studies CB-01-02/01 (NCT00679432), CB-01-02/02 (NCT00679380), or CB-01-02/06 (NCT01100112) who achieved ulcerative colitis disease activity…
- Trial name
- NCT00801723
- Testing
- Budesonide MMX 6 mg Tablet
- Where
- 58 sites in United States, Canada
- Volunteers
- 123 people
- Sponsor
- Bausch Health Americas, Inc.
Ulcerative Colitis
Dose Escalation and Remission (DEAR)
The proposed study will test whether increasing Lialda dose can reduce fecal calprotectin (FCP) levels, a marker of intestinal inflammation that is highly predictive of the risk of relapse among patients with quiescent ulcerative…
- Trial name
- DEAR (NCT00652145)
- Testing
- mesalamine
- Where
- 8 sites in United States
- Volunteers
- 119 people
- Sponsor
- James Lewis
Colitis, Ulcerative
A Study of the Efficacy and Safety of Etrolizumab Treatment in Maintenance of Disease Remission in Ulcerative Colitis (UC) Participants Who Are Naive to Tumor Necrosis Factor (TNF) Inhibitors
This Phase III, randomized, double-blind, parallel-grouped, placebo-controlled, multicenter study will investigate the efficacy and safety of etrolizumab in maintenance of remission in participants with moderately to severely…
- Trial name
- LAUREL (NCT02165215)
- Testing
- Etrolizumab
- Where
- 104 sites in United States, Brazil and 13 more
- Volunteers
- 359 people
- Sponsor
- Hoffmann-La Roche
Colitis, Ulcerative
A Phase 2a, Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Trial of IBD98-M
IBD98-M-2002 is a phase 2a , Randomized, Double blind, Placebo-controlled of IBD98-M Delayed Release capsules in subjects with Mild to Moderately Ulcerative Colitis to investigate the clinical efficacy of IBD98-M delayed release…
- Trial name
- NCT02493712
- Testing
- High dose, Low dose
- Where
- Italy
- Volunteers
- 51 people
- Sponsor
- Holy Stone Healthcare Co., Ltd
Ulcerative Colitis
Berberine Chloride in Preventing Colorectal Cancer in Patients With Ulcerative Colitis in Remission
This randomized, pilot phase I trial studies the side effects of berberine chloride in treating patients with ulcerative colitis and who are in remission (a decrease in or disappearance of signs and symptoms of cancer) to reduce…
- Trial name
- NCT02365480
- Testing
- Berberine Chloride, Laboratory Biomarker Analysis
- Where
- 2 sites in United States, China
- Volunteers
- 18 people
- Sponsor
- National Cancer Institute (NCI)
Ulcerative Colitis
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Acute Ulcerative Colitis
The objective of this study is to assess the efficacy and safety of adalimumab for the induction of clinical remission in subjects with moderately to severely active ulcerative colitis.
- Trial name
- NCT00385736
- Testing
- adalimumab
- Where
- 80 sites in United States, Austria and 11 more
- Volunteers
- 576 people
- Sponsor
- Abbott
Ulcerative Colitis
Ability to Maintain or Achieve Clinical and Endoscopic Remission With MMX Mesalamine Once Daily in Adults With Ulcerative Colitis
This study was designed to evaluate if subjects who achieve complete remission after 8 weeks of acute therapy with MMX mesalamine/mesalazine 4.8g/day given QD have better long-term outcomes and remain in remission longer compared…
- Trial name
- NCT01124149
- Testing
- MMX mesalamine/ mesalazine
- Where
- 105 sites in United States, Belgium and 13 more
- Volunteers
- 759 people
- Sponsor
- Shire
Ulcerative Colitis
Efficacy & Safety of Infliximab Monotherapy Vs Combination Therapy Vs AZA Monotherapy in Ulcerative Colitis (Part 1) Maintenance Vs Intermittent Therapy for Maintaining Remission (Part 2)(Study P04807)
Part 1 of this study is a 3-arm, randomized, active-controlled, parallel-group, multicenter, double-blind, double-dummy, 16-week study to compare the efficacy and safety of infliximab (IFX), as monotherapy or in combination with…
- Trial name
- NCT00537316
- Testing
- Infliximab (IFX), Azathioprine (AZA)
- Volunteers
- 242 people
- Sponsor
- Merck Sharp & Dohme LLC
Ulcerative Colitis
Efficacy and Safety of Adalimumab in Subjects With Moderately to Severely Active Ulcerative Colitis
This was a Phase 3, multicenter, randomized, double-blind, placebo-controlled trial designed to evaluate the efficacy and safety of the human anti-tumor necrosis factor (TNF) monoclonal antibody adalimumab (ADA) in patients with…
- Trial name
- NCT00408629
- Testing
- adalimumab
- Where
- 108 sites in United States, Argentina and 16 more
- Volunteers
- 518 people
- Sponsor
- Abbott
Ulcerative Colitis
A Study Evaluating the Effect of Filgotinib Dose De-escalation in Participants With Ulcerative Colitis (UC) in Remission
Participants who were in clinical remission on 200 milligram (mg) filgotinib once daily for at least 2 consecutive quarterly visits in the ongoing SELECTION-LTE study (GS-US-418-3899, NCT02914535), were planned to be rolled over…
- Trial name
- CAPYBARA (NCT05479058)
- Testing
- Filgotinib
- Where
- 50 sites in United States, Belgium and 11 more
- Volunteers
- 22 people
- Sponsor
- Lakefront Biotherapeutics NV
Active Ulcerative Colitis, Remission of Ulcerative Colitis
Canadian Active & Maintenance Modified Pentasa Study
The purpose of this study is to demonstrate that the new modified oral extended-release Pentasa® 500mg tablet is at least as efficacious as the currently marketed Pentasa® 500mg tablet in active mild to moderate Ulcerative…
- Trial name
- CAMMP (NCT00603733)
- Testing
- 5-ASA (5-Aminosalicylate)
- Where
- 27 sites in Canada
- Volunteers
- 288 people
- Sponsor
- Ferring Pharmaceuticals
Ulcerative Colitis
Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis
The purpose of this study is to determine whether low dose Asacol® (27 mg/kg - 71 mg/kg) and high dose Asacol® (53 mg/kg - 118 mg/kg) are safe and effective when dosed as 400 mg delayed-release tablets given twice daily for 26…
- Trial name
- CAMPIII (NCT01004185)
- Testing
- Asacol 400 mg
- Where
- 51 sites in United States, Canada and 4 more
- Volunteers
- 39 people
- Sponsor
- Warner Chilcott
Ulcerative Colitis
Study to Evaluate the Efficacy and Safety of Filgotinib in the Induction and Maintenance of Remission in Adults With Moderately to Severely Active Ulcerative Colitis
The primary objectives of this study are to evaluate the efficacy of filgotinib in the induction and maintenance treatment of moderately to severely active ulcerative colitis (UC) in participants who are biologic-naive and…
- Trial name
- SELECTION (NCT02914522)
- Testing
- Filgotinib, PTM filgotinib
- Where
- 343 sites in United States, Argentina and 38 more
- Volunteers
- 1,351 people
- Sponsor
- Gilead Sciences
Ulcerative Colitis
Vedolizumab Monotherapy Vs Combination Therapy With Tacrolimus in UC
The aim of this study is to assess if a combination therapy of tacrolimus and vedolizumab is superior to vedolizumab monotherapy for induction of remission in moderate to severe UC, and its effect on long and short-term outcomes…
- Trial name
- COVET (NCT02954159)
- Testing
- Tacrolimus, Vedolizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Medical College of Wisconsin
Ulcerative Colitis
HMPL-004 Maintenance Treatment in Subjects With Mild to Moderate Ulcerative Colitis
A study with an 8 week open label phase study followed by a year long placebo controlled maintenance phase in subjects with active mild to moderate ulcerative colitis (UC), with a modified Mayo Score 4-10 and an endoscopy…
- Trial name
- NATRUL-4 (NCT01882764)
- Testing
- HMPL-004
- Where
- United States
- Volunteers
- 66 people
- Sponsor
- Hutchison Medipharma Limited
Ulcerative Colitis
Mesalamine 2 g Sachet for the Maintenance of Clinical and Endoscopic Remission in Ulcerative Colitis (UC)
The purpose of this trial was to investigate the safety and efficacy of mesalamine 2 g extended release granules (sachet) once a day (QD) for maintenance of clinical and endoscopic remission in subjects with UC.
- Trial name
- NCT02522780
- Testing
- Mesalamine
- Where
- 96 sites in United States, Bulgaria and 9 more
- Volunteers
- 276 people
- Sponsor
- Ferring Pharmaceuticals